Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
The 78th World Health Assembly has been a whirlwind week for ADI as, after 18-months of advocacy, the World Health Assembly has agreed to extend the Global Action Plan on the Public Health Response to Dementia by 6-years, to 2031.
Lecanemab is the first therapy of its kind approved in the EU that could potentially slow the progression of Alzheimer’s disease. The use of lecanemab will now be considered by national payers, who will assess the treatment against further nationally determined criteria.
Results from the LUCIDTY Phase 3 study suggests initial positive results for early and mild to moderate Alzheimer’s Disease
‘Integrating palliative care for older adults’ was written with ADI, The Worldwide Hospice Palliative Care Alliance (WHPCA), SANAD Hospice Lebanon and Hamad Medical Corporation (HMC).
ADI warmly welcomes the positive initial data reported today by Eisai and Biogen on the CLARITY AD global Phase 3 clinical trial of lecanemab.
ADI, alongside Newcastle University and the London School of Economics, is submitting an application to the WHO Expert Committee on the inclusion of anti-dementia medication and needs to hear from clinicians everywhere.
The project, launching 1 September, will aim to raise funds for ADI through the sale of a collection of photographs in the form of NFTs.
DY Suharya, ADI Regional director for Asia Pacific, will lead on a Values 20 (V20) work stream in preparation for the G20 summit, taking place on 15-16 November 2022.
If you are living with dementia, a carer, clinician, formal (paid) health or long-term care practitioner, we need to hear about your experience of post-diagnosis for the World Alzheimer Report 2022.
ADI is pleased to announce the formalisation of a long-standing collaboration with World Wide-FINGERS (WW-FINGERS) by joining in partnership to reduce the risk of dementia worldwide.